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Abstract
Background: Angotensin converting enzyme 2 (ACE2) is a newly discovered monocarboxypeptidase that
counteracts the vasoconstrictor effects of angiotensin II (Ang II) by converting Ang II to Ang-(1-7) in the kidney and
other tissues.
Methods: ACE2 activity from renal homogenates was investigated by using the fluorogenic peptide substrate
Mca-YVADAPK(Dnp)-OH, where Mca is (7-methoxycoumarin-4-yl)-acetyl and Dnp is 2,4-dinitrophenyl.
Results: We found that ACE2 activity expressed in relative fluorescence units (RFU) in the MF1 mouse is higher in the
male (M) compared to the female (F) kidney [ACE2 (RFU/min/μg protein): M 18.1 ± 1.0 versus F 11.1 ± 0.39; P <0 . 0 0 0 1 ;
n = 6]. Substrate concentration curves revealed that the higher ACE2 activity in the male was due to increased ACE2
enzyme velocity (Vmax) rather than increased substrate affinity (Km). We used the four core genotypes mouse model in
which gonadal sex (ovaries versus testes) is separated from the sex chromosome complement enabling comparisons
among XX and XY gonadal females and XX and XY gonadal males. Renal ACE2 activity was greater in the male than
the female kidney, regardless of the sex chromosome complement [ACE2 (RFU/min/μg protein): intact-XX-F, 7.59 ± 0.37;
intact-XY-F, 7.43 ± 0.53; intact-XX-M, 12.1 ± 0.62; intact-XY-M, 12.7 ± 1.5; n = 4-6/group; P < 0.0001, F versus M, by two-
way ANOVA]. Enzyme activity was increased in gonadectomized (GDX) female mice regardless of the sex chromosome
complement whereas no effect of gonadectomy was observed in the males [ACE2 (RFU/min/μg protein): GDX-XX-F,
12.4 ± 1.2; GDX-XY-F, 11.1 ± 0.76; GDX-XX-M, 13.2 ± 0.97; GDX-XY-M, 11.6 ± 0.81; n = 6/group]. 17b-oestradiol (E2)
treatment of GDX mice resulted in ACE2 activity that was only 40% of the activity found in the GDX mice, regardless of
their being male or female, and was independent of the sex chromosome complement [ACE2 (RFU/min/μgp r o t e i n ) :
GDX+E2-XX-F, 5.56 ± 1.0; GDX+E2-XY-F, 4.60 ± 0.52; GDX+E2-XX-M, 5.35 ± 0.70; GDX+E2-XY-M, 5.12 ± 0.47; n = 6/group].
Conclusions: Our findings suggest sex differences in renal ACE2 activity in intact mice are due, at least in part, to
the presence of E2 in the ovarian hormone milieu and not to the testicular milieu or to differences in sex
chromosome dosage (2X versus 1X; 0Y versus 1Y). E2 regulation of renal ACE2 has particular implications for
women across their life span since this hormone changes radically during puberty, pregnancy and menopause.
Introduction
The discovery of angiotensin converting enzyme 2
(ACE2) is less than a decade old [1-3]. In contrast to
angiotensin converting enzyme (ACE), which synthesizes
the potent vasoconstrictor, angiotensin II (Ang II)
through its dicarboxypeptidase activity acting on the
decapeptide angiotensin I, ACE2 catabolizes Ang II
through its monocarboxypeptidase activity (Figure 1).
Studies suggest ACE2 counters the adverse effects of
ACE action and that these two enzymes play a ying and
yang role in the physiological regulation of Ang II meta-
bolism and in disease pathologies such as hypertension,
progressive renal disease and diabetes [1,4,5].
Much evidence indicates that Ang II metabolism is
differentially regulated in males and females [6,7]. For
example, plasma renin activity is 27% higher in men
compared to women in a normotensive population [8]
and plasma renin concentration (measured at pH 6.5)
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tensive Lewis rats than in the females [9]. Studies also
suggest Ang II metabolism is differentially regulated in
the male and female kidney. In the normal rat kidney,
no sex differences in renal ACE activity were observed.
In contrast, renin concentration and neutral endopepti-
dase neprilysin were shown to be higher in the female
than the male, whereas renal ACE2 was markedly lower
in the female [9]. However, the cause of these sex differ-
ences in Ang II metabolism is not fully understood.
Sex differences in biology are due to the differences of
being exposed in utero and through development to a
male or female hormonal milieu. However, sex differ-
ences are also due to differences in sex chromosome
dosage (2X versus 1X and 0Y versus 1Y). Fibroblast-
based assays reveal expression heterogeneity among
females; approximately 15%-25% of human X-linked
genes escape X-inactivation fully or in part [10], although
only a small subset of these genes show higher expression
in females [11-13]. In mice, the percent of escape is less,
but it still occurs and, thus, could contribute to sex dif-
ferences in gene activity [13]. Another potential differ-
ence in the effects of the XX and XY sex chromosome
complement arises from parental imprinting. While the
X chromosomes in males are only imprinted maternally,
the X chromosomes in females are imprinting maternally
and paternally. Parental imprinting can exert major influ-
ences on gene function and have striking pathophysiolo-
gical consequences [14,15].
It has been difficult to isolate the effects of the gona-
dal hormones from the effects of the sex chromosomes
because the Y chromosome houses Sry,t h et e s t i s -
determining gene. However, in the four core genotypes
(FCG) mouse model, separating effects of the gonads
from the sex chromosomes is now possible [16]. In
FCG mice, the Y
- chromosome lacks Sry [16] and,
thus, XY
- mice develop ovaries. Inserting the Sry gene
onto an autosome enabled the creation of the XY
-Sry
mouse with testes. Breeding XX female mice with XY
-
Sry male mice results in the FCG: XX and XY
- gonadal
females and XXSry and XY
-Sry gonadal males.
Interestingly, ACE2 is located on the X chromosome
[17], which raises the possibility that differences in sex
chromosome dosage (2X versus 1X) could impact ACE2
activity due to escape from X-inactivation on the second
X or differences in parental imprinting. As the kidney is
one of the most abundant tissue sources of ACE2 [5],
after optimizing an ACE2 assay for mouse tissues, we
investigated the separate effects of the gonads and sex
chromosomes on ACE2 in the kidney using the FCG.
Methods
Animals
The mice used in these studies included the random-bred
MF1 wild type mouse, the FCG on the MF1 background
and ACE2 null mice (ACE2
-/-) on the C57BL/6 back-
ground. Studies were conducted in mice between 3-6
months old. MF1 breeders were purchased from Harlan
Laboratories (MD, USA). The FCG breeders were
received from Dr. Arthur P. Arnold’s laboratory at UCLA
(CA, USA). The ACE2
-/- mice originated from Dr. Susan
Gurley and Thomas Coffman at Duke University (NC,
USA) [18] but were received from Dr Eric. Lazartigues’
laboratory at Louisiana State University (LA, USA). All
mice were bred at Georgetown University as previously
described [18,19]. Since mice from each litter were dis-
tributed across groups, prenatal and postnatal environ-
ment and litter effects were distributed across groups and
genotypes. All mice were maintained on a phytoestrogen
free diet (Harlan) and given tap water ad libitum under
controlled conditions (12 h light/dark schedule at 24°C).
Although the diet was phytoestrogen free, it should be
noted that the tap water may have contained phytoestro-
gens although a recent study showed that more than 99%
of the phytoestrogens are removed from waste water by
the municipal treatment process [20]. All procedures
were approved by the Georgetown University Animal
Care and Use Committee.
Gonadectomy and 17b-estradiol (E2) treatment
Gonadectomies were conducted between 53-60 days of
age. Bilateral incisions were made under isoflurane
anaesthesia (Baxter Healthcare Corp, IL, USA), the vas-
cular supply was ligated and the gonads (either testes or
ovaries) were removed. The muscle layer was sutured
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Figure 1 Synthetic and catabolic pathways of Ang II.
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operated mice, the animals were subjected to surgery
and the gonads were manipulated but left intact. At the
time of gonadectomy, some GDX mice were treated
with E2 (oestradiol) for 1 month as described previously
[21] by inserting an E2 pellet (0.5 mg/90 days; Innova-
tive Research of America, FL, USA) subcutaneously
resulting in a dose of 5.6 μg/day.
Tissue homogenates
At the time of sacrifice, the kidneys, heart and lung
were removed and immediately homogenized in 5 vol/
tissue wet weight of ice-cold lysis buffer (50 mM MES,
300 mM NaCl, 10 μMZ n C l 2, 0.01% Bis, pH 6.5). Pro-
tease inhibitors were also included in lysis buffer: 0.50
μg/mL pepstatin A, 0.25 μg/mL leupeptin, 0.1 mg/mL
bacitracin and 0.57 mmol PMSF (Sigma, MO, USA).
After centrifuging the homogenate at 12,000 × g for 10
min at 4°C, the supernatant was removed, aliquoted in
20 μL fractions and frozen at -80°C. The protein content
in sample lysates was measured using the Bio-Rad pro-
tein reagent (Bio-Rad Laboratories, CA, USA).
ACE2 enzyme activity
Renal ACE2 activity was measured using the caspase-1
fluorogenic substrate 7-Mca-Tyr-Val-Ala-Asp-Ala-Pro-
L y s ( D n p ) - O H( R & DS y s t e m s ,M N ,U S A ) ,w h e r eM c a
is (7-methoxycoumarin-4-yl)-acetyl and Dnp is 2,4-
dinitrophenyl. Upon binding this substrate, ACE2
removes the COOH-terminal Dnp moiety via reso-
nance energy transfer, unleashing the fluorescence
inherent in Mca [22]. Heart and lung ACE2 activity
were measured using the fluorogenic substrate Mca-
Ala-Pro-Lys(Dnp)-OH (Anaspec, CA, USA).
Each well in a 96 well microtitre plate contained
70 μL of reaction buffer (1 M NaCl, 0.5 mM ZnCl2,
75 mM Tris, pH 7.5) in the presence of vehicle or inhi-
bitors of ACE and/or ACE2, unless otherwise specified.
Total peptidase enzyme activity was measured in the
presence of vehicle (reaction buffer). Non-ACE activity
was defined as peptidase activity measured in the pre-
sence of 10 μM captopril - an ACE inhibitor (Sigma
Chemical Co, MO, USA). Nonspecific peptidase activity
was defined as peptidase activity measured in the pre-
sence of 10 μMc a p t o p r i la n d1 0μM MLN-4760 - an
ACE2 inhibitor (gift from Millennium Pharmaceuticals,
MA, USA). Specific ACE2 activity was defined as non-
ACE activity minus nonspecific peptidase activity.
Immediately after adding 10 μL of fluorogenic substrate,
20 μL of renal homogenate was added to each well in
order to reach a final concentration of 30 μMs u b s t r a t e
and 10 μg renal protein/100 μL/well, unless otherwise
stated. Product formation was determined at 37°C by
following the fluorescence as a function of time using a
fluorescence plate reader (FLUOstar Omega, BMG LAB-
TECH Inc, NC, USA) at an excitation wavelength of
320 nm and an emission wavelength of 410 nm.
In order to confirm assay specificity, we compared ACE2
activity in the kidneys of ACE2 wildtype (ACE2
+/+)a n d
knockout (ACE2
-/-) mice [18]. Under these conditions, the
amount of fluorescence obtained was less than 3% in the
knockout female compared to the wild type mouse [rela-
tive fluorescence units (RFU)/min/μgp r o t e i n :A C E 2
+/+,
13.9 ± 0.26 versus ACE2
-/-, 0.420 ± 0.014; P < 0.001; n =
2/group]. Initial velocities were determined from the rate
of fluorescence increase over the 50-100 min time course
corresponding to the linear range of the assay. To further
confirm the fluorescence assay for ACE2 activity, we con-
tracted with the Wake Forrest University Hypertension
Core Laboratory and measured the kinetics of hydrolysis
of [
125I]-Ang II (from 500 pM to 10 μM) to [
125I]-Ang-
(1-7) (Figure 1) in male and female MF1 renal homoge-
nates using reverse-phase high-performance liquid chro-
matography to quantitate angiotensin peptides as
previously described [23].
ACE2 Western blot
ACE2 protein was determined by Western blot using an
ACE2 goat polyclonal antibody (R&D Systems). Protein
(80 μg) extracted from mouse whole kidney was heated
(95°C, 10 min) in a Laemmli buffer, separated on Criterion
precasting Tris-HCl gels (Bio-Rad Laboratories) and then
blotted onto nitrocellulose. Nonspecific binding was
blocked with nonfat dry milk (5%) before ACE2 protein
was detected using a goat polyclonal antibody (R&D Sys-
tems, Inc) and a rabbit anti-goat horseradish peroxidase-
coupled second antibody (Kirkegaard and Perry Labora-
tories, Inc, MD, USA). Visualization was carried out with
chemiluminescence (LumiGLO peroxidase chemilumines-
cent substrate, Kirkegaard and Perry Laboratories, Inc)
using X-ray film (CL-XPOSURE, Thermo Scientific, IL,
USA). ACE2 protein was expressed in arbitrary units (AU)
of immunoreactive ACE2 protein normalized to b-actin.
In order to confirm assay specificity, we compared
ACE2 protein in the kidneys of ACE2
+/+ and ACE2
-/-
mice [18]. Under these conditions, the amount of
immunoreactive protein obtained was less than 0.9% in
the knockout female compared to the wild type mouse
[AU: ACE2
+/+,9 4 . 0±4 . 0v e r s u sA C E 2
-/-, 0.890 ± 0.36;
P < 0.01; n = 2/group].
ACE2 mRNA expression
ACE2 mRNA was determined in renal extracts by real-
time polymerase chain reaction (PCR) using the ABI
Prism 7700 Sequence Detection System (Applied Biosys-
tems, CA, USA). Total RNA was extracted with TRIzol
reagent (Invitrogen, CA, USA). First strand cDNA was
made from total RNA using iScript cDNA synthesis kit
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transcriptase, oligo(dT) and random hexamers. The PCR
reaction mixture included cDNA, TaqMan Universal PCR
Master Mix (Applied Biosystems), forward and reverse pri-
mers (300 nM each) and 10 μMp r o b e[ Forward primer:
5’-TCT GGG CAA ACT CTA TGC TGA CT-3’; Reverse
primer: 5’-GGC TGT CAA GAA GTT GTC CAT TG-3’;
and Probe: 6 FAM- CGG AAA GTT GTC TGC CAC
CCC ACA-TAMRA]. PCR reactions without reverse tran-
scription were included to control for contamination by
genomic DNA. ACE2 mRNA was expressed in pg/μgt o t a l
RNA normalized to 18 S ribosomal RNA.
In order to confirm assay specificity, we compared
ACE2 mRNA in the kidneys of ACE2
+/+ and ACE2
-/-
mice [18]. Under these conditions, the amount of
mRNA obtained was less than 2% in the knockout
female compared to the wild type mouse [pg/μgt o t a l
RNA: ACE2
+/+, 3.71 ± 0.46 versus ACE2
-/-, 0.050 ±
0.005; P < 0.001; n = 2].
Statistics
Data are expressed as means ± standard error of mean.
Enzyme kinetics were analysed using Prism 4.0 (Graph-
Pad Software Inc, CA, USA) to generate Vmax and t1/2
values from the Michaelis-Menten equation: V = Vmax
[S]/([S]+Km), where V = velocity; Vmax =m a x i m u m
velocity; [S] = substrate concentration; Km = Michaelis-
Menten constant. T-tests were used to compare one
independent variable. Two-way ANOVA and three-way
ANOVA analysis were used to compare two and three
independent variables, respectively (Sigma Stat Build
3.5.0.54, Systat Software Inc, IL, USA). Differences were
considered statistically significant at P < 0.05.
Results
Dependence of mouse renal ACE2 activity on pH
ACE2 activity in female MF1 wild type mice renal
homogenates was highly sensitive to pH and was opti-
mal between pH 7.0 and 7.5 (Figure 2). The pH had a
marked effect on the time course of enzyme product
formation (RFU; Figure 2A). At pH 7.5, ACE2 product
formation was linear with time up to 175 min, whereas
at pH 7.0 product formation was linear only up to 50
min and at pH 5.5 the duration of the linear range was
even shorter (25 min). This pH dependency of ACE2
activity is striking when product formation at 150 min is
plotted as a function of pH (Figure 2B). Thus for all
subsequent experiments, renal ACE2 activity was mea-
sured at pH 7.5. ACE2 enzyme activity in male renal
homogenates was optimal between pH 7.0 and 7.5, simi-
lar to the data in the female (data not shown).
Sexual dimorphism in dependence of mouse ACE2
activity on renal protein
The relationship between renal ACE2 product formation
and time was affected by the protein concentration in
male (Figure 3A) and female (Figure 3B) MF1 wild type
mice. There was a positive correlation between product
formation and time up to 120 min for protein concen-
trations < 20 μg. However, this relationship became
negative above this protein concentration. Thus, for all
subsequent experiments, ACE2 activity in renal homoge-
nates was measured using 10 μg of protein. Data from
the 40 min reaction time point was collected and
plotted in Figure 3C. Comparison of the protein dose
response curves in males and females within this posi-
tive and linearly correlatedr a n g eo ft h ea s s a ys h o w e d
that ACE2 activity in the male kidney was 1.9-fold
greater than the female (Figure 3C).
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Figure 2 Dependence of renal angiotensin converting enzyme
2 (ACE2) activity on pH in the MF1 mouse. (A) Effect of pH on
the time course of product formation in the female mouse. Data are
representative of three experiments performed in triplicate. (B) Effect
of pH on enzyme product formation at 150 min; *P < 0.05 and **P
< 0.01 versus pH 7.5, n = 4/group.
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Page 4 of 11Sexual dimorphism in kinetics of renal ACE2 activity
The relationship between renal ACE2 activity and time
was affected by the substrate concentration in male
(Figure 4A) and female (Figure 4B) MF1 wild type mice.
There was a positive correlation between enzyme activ-
ity and time up to 180 min for substrate concentrations
<3 0μM. However, this relationship became negative
above this substrate concentration in renal tissue from
both sexes. Thus, for all subsequent experiments, renal
ACE2 activity was measured using a substrate concen-
tration of 30 μM. In order to determine whether the dif-
ference in renal ACE2 activity between males and
females (Figure 3C) was due to differences in enzyme
substrate affinity (Km) or to maximum enzyme velocity
(Vmax), we calculated the Km and Vmax from ACE2 sub-
strate dose response curves from 3.75 to 30 μM
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Figure 3 Dependence of renal angiotensin converting enzyme
2 (ACE2) activity on protein concentration in the MF1 mouse.
Effect of protein concentration on the time course of product
formation in (A) male and (B) female mice. Data are representative
of three experiments performed in triplicate. (C) Effect of protein
concentration on product formation at 40 min in male and female
mice; *P < 0.01 versus female by t-test; two-way ANOVA revealed a
significant effect of protein (P < 0.0001) and sex (P < 0.0001) on
renal ACE2 activity; n = 4/group.
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Figure 4 Dependence of renal ACE2 activity on substrate
concentration in the MF1 mouse. Effect of substrate
concentration on the time course of product formation in (A) male
and (B) female mice. Data are representative of three experiments
performed in triplicate. (C) Effect of substrate concentration on
product formation at 40 min in male and female mice. Also shown
is the determination of Km and Vmax;* P < 0.001 versus female by t-
test; n = 4-5/group. Two-way ANOVA revealed a significant effect of
substrate (P < 0.0001) and sex (P < 0.0001) on renal ACE2 activity.
Liu et al. Biology of Sex Differences 2010, 1:6
http://www.bsd-journal.com/content/1/1/6
Page 5 of 11substrate concentration in male and female MF1 mice
(Figure 4C). No sex differences were observed in the
ACE2 Km [μM: male, 11.1 ± 0.93 versus female, 9.92 ±
0.56; not significant (ns); n = 4-5/group]. In contrast,
the Vmax was 1.9-fold higher in the male kidney [RFU/
min/μg: male, 34.5 ± 2.0 versus female, 18.4 ± 1.4; *P <
0.001; n = 4-5/group]. This sexual dimorphism in renal
Vmax ACE2 activity, but not the Km, was confirmed by
our findings using reverse-phase high-performance
liquid chromatography to measure the enzyme kinetics
of [
125I]-Ang II metabolized to [
125I]-Ang-(1-7) [Vmax
(fmol/mg/min): male, 7.59 ± 0.63 versus female, 5.14 ±
0.55, P < 0.05; Km (μM): male, 3.43 ± 0.85 versus female,
3.36 ± 1.1, ns; n = 4/group].
Comparison of ACE2 activity in male and female kidney,
heart and lung tissues
In order to determine whether the sex differences in
renal ACE2 activity were specific to the kidney, we opti-
m i z e da nA C E 2a s s a yi nt h eh e a r ta n dl u n gf r o mM F 1
wild type mice as these tissues are known to abundantly
express ACE2 [5]. ACE2 activity was optimal at pH 7.5
and linear up to 80 μg protein for both myocardial and
lung tissues (data not shown). There was a positive cor-
relation between enzyme activity and time up to 180
min for substrate concentrations up to 30 μM. However,
this relationship became negative above this point in
both tissues. Therefore, we measured initial linear velo-
city (RFU/min μg protein) for ACE2 at 30 μM substrate
for all three tissues (Figure 5).
Under these conditions, ACE2 activity was 1.6-fold
higher in the male kidney [ACE2 (RFU/min/μg protein):
male, 18.1 ± 1.0 versus female, 11.1 ± 0.39; P < 0.0001;
n = 6]. In contrast, no significant differences in ACE2
activity between male and female mice were detected in
the heart [ACE2 (RFU/min/μg protein): male, 3.41 ±
0.37 versus female, 3.22 ± 0.26; n =5 ]a n dl u n g[ A C E 2
(RFU/min/μg protein): male, 6.03 ± 0.54 versus female,
5.07 ± 1.1; n = 5].
Sexual dimorphism in renal ACE2 protein and mRNA
expression
In order to determine whether the difference in renal
ACE2 activity between males and females was due to
differences in protein expression, we performed Western
blot analysis of ACE2 in renal homogenates from male
and female mice (Figure 6A). Immunoreactive renal
ACE2 protein was expressed at a 1.5-fold higher level in
males.
In order to determine whether the difference in renal
ACE2 protein expression between males and females
was due to differences in mRNA expression, we per-
formed real-time PCR on renal ACE2 in male and
female mice (Figure 6B). Renal ACE2 mRNA was
expressed at a 1.5-fold higher level in male mice.
Sex chromosome-independent ovarian and E2-mediated
effects on renal ACE2 activity
In order to determine the effect of gonadal sex (testes
versus ovaries) independently of the sex chromosome
complement (XX versus XY), we compared renal ACE2
activity in gonadally intact FCG at 4 months of age
[ACE2 (RFU/min/μg protein): intact-XX-F, 7.59 ± 0.37;
intact-XY-F, 7.43 ± 0.53; intact-XX-M, 12.1 ± 0.62;
intact-XY-M, 12.7 ± 1.5; n =4 - 6 / g r o u p ;F i g u r e7 ] .A n a -
lysis by two-way ANOVA (factors of sex, male versus
female and sex chromosome complement, XX versus
XY) showed that regardless of being XX or XY, intact
males had approximately 1.6-fold higher renal ACE2
activity than intact females (P < 0.0001) and there was
no gonad-independent effect of the sex chromosome
complement on enzyme activity (Figure 7).
In order to determine the effect of gonadectomy inde-
pendently of the sex chromosome complement, we mea-
sured renal ACE2 activity 1 month after gonadectomy in
the FCG [ACE2 (RFU/min/μg protein): GDX-XX-F, 12.4
± 1.2; GDX-XY-F, 11.1 ± 0.76; GDX-XX-M, 13.2 ± 0.97;
GDX-XY-M, 11.6 ± 0.81; n = 6/group; Figure 7]. Analy-
sis by three-way ANOVA (factors of sex, male versus
female; sex chromosome complement, XX versus XY
and, gonad state, GDX versus intact) showed that there
was no effect of gonadectomy or the sex chromosomes
on ACE2 activity in the males whereas the GDX female
mice had approximately 1.6-fold higher renal ACE2
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Figure 5 Angiotensin converting enzyme 2 (ACE2) activity in
the kidney, heart and lung of the MF1 mouse. Comparison of
ACE2 activity in male and female mice tissue homogenates using
10 μg kidney and 40 μg heart and lung protein and 30 μM
substrate concentration for all three tissues; *P < 0.001 versus
female by t-test; n = 5/group.
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Page 6 of 11activity than the intact females (P <0 . 0 0 1 )r e g a r d l e s so f
being XX or XY.
In order to determine the effect of 17b-estradiol (E2)
treatment in GDX mice independently of the sex chromo-
some complement, we measured the renal ACE2 activity
after treating GDX mice with E2 (5.6 μg/day) for 1 month
[ACE2 (RFU/min/μg protein): GDX+E2-XX-F, 5.56 ± 1.0;
GDX+E2-XY-F, 4.60 ± 0.52; GDX+E2-XX-M, 5.35 ± 0.70;
GDX+E2-XY-M, 5.12 ± 0.47; n = 6/group; Figure 7]. Ana-
lysis by three-way ANOVA (factors of sex, male versus
female; sex chromosome complement, XX versus XY and
E2 treatment, GDX versus GDX+E2)s h o w e dt h a tE 2
reduced renal ACE2 activity by 56%-59% compared to the
GDX mice and that the effect of E2 (P < 0.001) was inde-
pendent of sex and the sex chromosomal complement.
Discussion
In this study, we initially optimized a fluorescent ACE2
assay for the mouse kidney. ACE2 activity was optimal
at a pH of 7.5. Major reductions in enzyme activity
occurred at 0.5 units above or below this pH. Using this
same substrate, recombinant soluble human ACE2 has
previously been shown to be strongly pH dependent,
though the optimal pH for human ACE2 was 6.5 [24].
Assaying ACE2 in mouse renal homogenates at a pH of
6.5 resulted in > 95% inhibition of the maximal ACE2
activity. Thus, the pH optimum for ACE2 activity is
dependent upon the species (human versus mouse) or
on the source of the enzyme (recombinant versus renal
homogenates). This discrepancy in pH dependence may
be an important consideration when comparing wild
type ACE2 activity in mice to ACE2 activity in mice
overexpressing the human form of the enzyme [25].
This enzyme’s strong pH sensitivity may reflect the
importance of Arg
273 and His
345,w h i c ha r et w ob a s i c
residues in ACE2 that are highly conserved across spe-
cies including Drosophiila, rabbit, mouse, rat and
human [2]. Arg
273 plays a key role in substrate affinity
and His
345, by acting as a hydrogen bond donator/
acceptor in the peptide intermediate, plays a critical role
in the enzymatic reaction [26].
Renal homogenates above 20 μg protein resulted in a
loss of assay linearity with respect to time, suggesting
that some tissue factor(s) achieves sufficient concentra-
tion to inhibit the assay above this amount. This factor
may be similar to the small, hydrophilic and cationic
endogenous inhibitor of ACE2 that was recently found
in human plasma [27].
The ACE2 enzyme was subject to substrate inhibition
at substrate concentrations above 30 μM. This phenom-
enon happens for 20% of all known enzymes and is
usually due to the binding of two substrate molecules to
the enzyme [28]. At low substrate concentrations, only
one substrate molecule binds and normal enzyme
kinetics occur. In contrast, when a second substrate
binds due to excess substrate, enzyme catalysis is often
inhibited. Thus, some studies of ACE2 activity in mouse
kidney in which 100 μg of renal homogenates [29] or
100 μM substrate [30] were used may be confounded by
the presence of tissue inhibitors or substrate inhibition.
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Figure 6 Angiotensin converting enzyme 2 (ACE2) protein and
messenger RNA (mRNA) expression in the MF1 mouse kidney.( A )
Quantitation of ACE2 protein expression from Western blots (upper) of
male and female mouse renal homogenates; *P <0 . 0 5v e r s u sf e m a l e ;n
= 7/group. (B) Quantitation of renal ACE2 mRNA expression
determined by real-time polymerase chain reaction in male (n =5 )
and female (n = 7) mouse kidney; *P <0 . 0 5v e r s u sf e m a l e .
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Page 7 of 11Under these assay conditions, we found that ACE2
activity is sexually dimorphic in the kidney. Male mice
have higher levels of renal ACE2 activity. This difference
in activity is due to a higher Vmax in the male compared
to the female kidney and not to sex differences in the
affinity of the substrate for the enzyme. These findings
support a previous study in normotensive Lewis rats,
which showed that ACE2 activity in the male renal cor-
tex was higher when compared to the female rat [9]. It
will be interesting to determine if this sexual dimorph-
ism in renal ACE2 activity is tightly conserved across
mammalian species including humans or whether it is
specific to rodents.
Although ACE2 activity is higher in the male kidney
under normal conditions, it does not necessarily mean
this would be the case under pathological conditions.
Studies have shown that renal ACE2 is up- [31] and
down-regulated [32] in disease pathologies. Given our
finding of sex differences in basal renal ACE2 activity, it
is imperative to determine if there is also sexual
dimorphism in renal ACE2 regulation under pathologi-
cal conditions.
Apparently, this sex difference in renal ACE2 activity
is not found in all tissues expressing the enzyme since
no significant differences in myocardial or lung ACE2
activity were observed in these same male and female
mice under our experimental conditions. The lack of
sexual dimorphism in mouse heart and lung ACE2
activity is similar to the findings of studies of cardiac
ACE2 in the Lewis rat [9] and to lung ACE2 in the
Sprague Dawley rat [33], since no differences in ACE2
activity between males and females were observed in
these tissues. Our findings of tissue-specific sexual
dimorphism in renal ACE2 activity also support a report
that showed that ovarian hormones down-regulated
ACE2 mRNA expression in the mouse kidney but not in
the lung [34].
The higher ACE2 Vmax in male kidneys compared to
females is likely due to higher levels of renal ACE2 pro-
tein expression since male kidneys expressed more renal
ACE2 protein than the female kidneys. The similarity in
the sex difference ratio (male:female) between protein
(1.5-fold) and mRNA (1.5-fold) suggests sex differences
in ACE2 protein expression are a direct result of sex dif-
ferences in the rate of ACE2 mRNA transcription. Thus,
these findings also suggest that renal ACE2 is differen-
tially regulated at the transcriptional level in males and
females. Interestingly, the sex difference ratio for
enzyme activity (1.9-fold) was higher than the sex differ-
ence ratio for protein and mRNA expression. This find-
ing raises the possibility that the enzyme is differentially
modified after protein synthesis in males and females in
such a way as to alter the enzyme activity since the sex
difference ratio for enzyme activity is amplified by
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Figure 7 Renal angiotensin converting enzyme 2 (ACE2) activity in the four core genotypes (FCG) in the intact and GDX state treated
with and without oestradiol (E2). Shown are the mean ± standard error of mean for renal ACE2 activity in gonadally intact (open bars), GDX
(striped bars) and E2 treated GDX (hatched bars) FCG mice; n = 6/group. ANOVA analyses revealed a significant effect of sex (P < 0.001, *intact-
female versus intact-male), gonadectomy in the female (P < 0.001, #intact-female versus GDX-F) and E2 treatment in all GDX mice (P < 0.001,
‡GDX+E2 versus GDX) on renal ACE2 activity (see Results for details).
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Page 8 of 111.3-fold compared to the sex difference ratio in protein
or mRNA. The resolved crystal structure of ACE2 [35]
suggests six of the seven potential sites [3] are glycosy-
lated, although there are no published studies to date
that explain how glycosylation alters enzyme activity.
Recently, ACE2 has been shown to bind calmodulin
through a calmodulin binding domain within the cyto-
plasmic tail. Upon binding calmodulin, ACE2 ectodo-
main shedding occurs which leads to as increased
release of the catalytically active soluble form of the
enzyme [36]. However, there are no reports to date on
how calmodulin binding affects ACE2 activity in the
kidney.
T h em a j o rf i n d i n go fo u rs t u d yw a st h a ts e xd i f f e r -
ences in renal ACE2 activity are caused by the female-
specific effects of the ovary and in particular, the pre-
sence of E2 and the fact that this effect is independent
of the sex chromosome complement or gonadal sex of
the animal. Previously, the effects of the gonads were
not separable from the effects of the sex chromosomes.
That is, regulation of ACE2 activity by gonadectomy
could not rule out the possibility that the effect of gona-
dectomy was really an effect of differences in X or Y
dosage that were unmasked in the absence of the
gonads. The FCG model, however, enables dissection of
potential gonadal effects from potential sex chromosome
effects. Thus, we were able to unequivocally demon-
strate that ACE2 activity is higher in the male kidney
compared to the female because of the presence of ovar-
ies and the ovarian hormone E2 and not because of the
differences in sex chromosome dosage (2X versus 1X or
0Y versus 1Y). As ACE2 expression was not higher in
mice with two X chromosomes relative to mice with
one X chromosome, the findings suggest that ACE2
does not escape X-inactivation, at least not in the
mouse tissues examined [13]. It remains possible, how-
ever, that ACE2 is regulated by X chromosome dosage
in humans since there are a greater number of genes
that escape X-inactivation in the human X chromosome
[10]. Furthermore, the lack of a difference between
G D Xg o n a d a lm a l e sa n df e m a l e s ,a n dt h e i re q u a l
response to oestradiol as adults, suggest that there are
no major organizational effects of gonadal hormones on
renal ACE2 activity. Apparently, sex differences in the
in utero hormonal milieu or in the hormonal milieu
during prepubertal development do not permanently
alter renal ACE2 activity. Moreover, the fact that E2
treatment lowered ACE2 activity in GDX male mice to
t h es a m ee x t e n ta sG D Xf e m a le mice indicates the this
attenuating effect of E2 on renal ACE2 activity is inde-
pendent of any organizational effects resulting from sex
differences in the in utero hormonal milieu.
Previously, we found that ovariectomy attenuated
renal ACE2 activity in a rat model of progressive renal
disease and that this effect was prevented by E2 treat-
ment [37]. The finding that renal ACE2 is differentially
regulated by E2 under normal and disease conditions
suggests the enzyme plays different physiological roles
in the normal and disease state. It would be interesting
in future studies to determine if compensatory actions
of ACE2 that have been described in disease states, such
as diabetes [4], is sexually dimorphic. Do males up-regu-
late renal ACE2 to a greater extent than females in renal
disease states? Is this a necessary compensation for the
greater renal injury experienced by the male kidney to
the same insult? It is known that the male kidney is
more susceptible to renal disease pathology than the
female in humans [38] and in animal models [39]. Alter-
natively, could sexual dimorphism in the ability to up-
regulate ACE2 contribute to the sex differences in renal
injury [40]?
Ovarian and, in particular E2 regulation of renal
ACE2, raises the possibility that the enzyme is differen-
tially regulated in women across their life span since the
ovarian hormone milieu radically changes from birth to
menarche, during pregnancy and through the meno-
pause transition. In fact, renal ACE2 activity has been
shown to be upregulated during pregnancy in Sprague
Dawley rats [41]. Thus, dysregulation of the ovarian hor-
mone milieu may increase susceptibility for diseases
involving the renin angiotensin system and may have
particular repercussions for postmenopausal women and
women with premature ovarian failure. However, it is
important to note that, although we did not find that
removing the testes impacted renal ACE2 activity, this
study can not rule out the possibility that ACE2 in male
kidneys is regulated by other factors associated with
development and ageing.
This study was conducted in a mouse model that does
not carry any known mutations that increase susceptibil-
ity to disease. Thus, it remains possible that the
mechanisms underlying the sex differences in renal
ACE2 activity disappear or are augmented by pathophy-
siology. In fact, we previously reported that, in the renal
wrap model of hypertension-associated renal disease,
ovariectomy decreased renal ACE2 activity and protein
expression while E2 replacement prevented these effects
in the Sprague Dawley rat [37]. Furthermore, E2 treat-
ment of ovariectomized Sprague Dawley rats was shown
to increase the levels of cardiac ACE2 protein expres-
sion under conditions of deocycorticosterone acetate-
induced hypertension and cardiac remodelling [42]. In
the pathophysiological state, where a role for ACE2 has
been implicated, sex differences in the degree of injury-
induced down-regulation of ACE2 or in the ability to
up-regulate ACE2 as a defence mechanism could be key
factors that have major implications for diabetes [4] and
other disease pathologies such as hypertension [1].
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After optimizing an ACE2 assay in mouse tissue, this
study found that the sex difference in basal ACE2 activ-
ity is selective for the kidney; males have higher renal
ACE2 activity than females whereas, under normal con-
ditions, no sex differences in ACE2 activity were
detected in the heart and lung. The higher renal ACE2
activity in males is probably due to sex differences in
both post-transcriptional and post-translational mechan-
isms of gene regulation. Most importantly, our study
demonstrates unequivocally that ACE2 is lower in the
female kidney because of the effects of the ovary and is
due, at least in part, to the presence of E2 and not
because of testicular effects or the sex chromosome
complement. These findings suggest new therapeutics
that target ACE2 need take into account the ovarian
hormone milieu across the female lifespan.
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